<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='195'><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10593">Meningitec</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1000</Patients><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Trial id="9859"/><TrialEndDateActual>2008-03-26 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-03-26 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1000</Patients><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Trial id="9859"/><TrialEndDateActual>2008-03-26 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-03-26 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Trial id="79465"/><TrialEndDateActual>2012-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1783</Patients><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Trial id="11526"/><TrialEndDateActual>2009-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-05-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1128</Patients><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Trial id="9949"/><TrialEndDateActual>2009-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-04-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>165</Patients><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><Trial id="15333"/><TrialEndDateActual/><TrialEndDateCalc>1998-06-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><Trial id="17509"/><TrialEndDateActual/><TrialEndDateCalc>1999-07-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>330</Patients><ProtocolTitle>Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes</ProtocolTitle><Trial id="11963"/><TrialEndDateActual>2006-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>869</Patients><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><Trial id="172270"/><TrialEndDateActual>2015-09-17 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-17 00:00:00</TrialEndDateGiven><TrialStartDate>2014-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1560</Patients><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><Trial id="161697"/><TrialEndDateActual>2016-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="41069">second-generation MMR vaccine, Berna</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>467</Patients><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><Trial id="17279"/><TrialEndDateActual/><TrialEndDateCalc>2007-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Trial id="10223"/><TrialEndDateActual>2009-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-12-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Trial id="91153"/><TrialEndDateActual>2015-08-18 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-08-18 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Trial id="203343"/><TrialEndDateActual>2015-12-22 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-02-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-12-22 00:00:00</TrialEndDateGiven><TrialStartDate>2014-08-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Trial id="10223"/><TrialEndDateActual>2009-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-12-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>600</Patients><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><Trial id="307614"/><TrialEndDateActual>2019-04-02 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-04-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2019-04-02 00:00:00</TrialEndDateGiven><TrialStartDate>2017-10-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6621">Havrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Trial id="79465"/><TrialEndDateActual>2012-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59852">Pentaxim</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>2475</Patients><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Trial id="340960"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-24 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="75100">MV-CHIK</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>263</Patients><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><Trial id="268409"/><TrialEndDateActual>2018-04-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-04-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-04-16 00:00:00</TrialEndDateGiven><TrialStartDate>2016-08-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Trial id="233238"/><TrialEndDateActual/><TrialEndDateCalc>2017-03-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="99042">double viral vaccine (measles/rubella), Bio-Manguinhos/Fiocruz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><Trial id="206205"/><TrialEndDateActual>2016-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-03-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12813">Rotarix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Trial id="233238"/><TrialEndDateActual/><TrialEndDateCalc>2017-03-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="60890">SA-14-14-2</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>628</Patients><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><Trial id="269874"/><TrialEndDateActual/><TrialEndDateCalc>2018-04-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2017-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2017-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Trial id="203343"/><TrialEndDateActual>2015-12-22 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-02-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-12-22 00:00:00</TrialEndDateGiven><TrialStartDate>2014-08-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>869</Patients><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><Trial id="172270"/><TrialEndDateActual>2015-09-17 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-12-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-09-17 00:00:00</TrialEndDateGiven><TrialStartDate>2014-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>822</Patients><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Trial id="60653"/><TrialEndDateActual>2001-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2001-12-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2001-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2000-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1390</Patients><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><Trial id="15243"/><TrialEndDateActual/><TrialEndDateCalc>2001-03-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-09-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>21</Patients><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><Trial id="15250"/><TrialEndDateActual>2001-10-10 00:00:00</TrialEndDateActual><TrialEndDateCalc>2000-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2001-10-10 00:00:00</TrialEndDateGiven><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56585">Vaxelis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Trial id="85664"/><TrialEndDateActual>2013-09-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-27 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Trial id="79465"/><TrialEndDateActual>2012-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44408">polio vaccine, Sanofi Pasteur</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Trial id="77052"/><TrialEndDateActual>2013-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-09-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>559</Patients><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Trial id="11387"/><TrialEndDateActual/><TrialEndDateCalc>2007-05-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2005-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1551</Patients><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><Trial id="60684"/><TrialEndDateActual>2000-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2000-10-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2000-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>1999-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Trial id="85664"/><TrialEndDateActual>2013-09-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-27 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Trial id="94105"/><TrialEndDateActual>2015-04-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-05-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-04-16 00:00:00</TrialEndDateGiven><TrialStartDate>2012-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="83793">Trivivac</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants</ProtocolTitle><Trial id="104131"/><TrialEndDateActual/><TrialEndDateCalc>2014-03-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2015-08-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2015-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><Trial id="15317"/><TrialEndDateActual/><TrialEndDateCalc>1999-06-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Trial id="79465"/><TrialEndDateActual>2012-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><Trial id="15335"/><TrialEndDateActual/><TrialEndDateCalc>1988-06-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1986-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="6621">Havrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Trial id="203343"/><TrialEndDateActual>2015-12-22 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-02-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-12-22 00:00:00</TrialEndDateGiven><TrialStartDate>2014-08-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="22877">RotaTeq</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>2475</Patients><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Trial id="340960"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-24 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Trial id="44865"/><TrialEndDateActual>2008-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-08-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17674">Infanrix Quinta</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Trial id="233238"/><TrialEndDateActual/><TrialEndDateCalc>2017-03-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>600</Patients><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><Trial id="307614"/><TrialEndDateActual>2019-04-02 00:00:00</TrialEndDateActual><TrialEndDateCalc>2019-04-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2019-04-02 00:00:00</TrialEndDateGiven><TrialStartDate>2017-10-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="99518">JVC-001</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A phase III clinical trial of JVC-001 for the prevention of measles, mumps and rubella infection</ProtocolTitle><Trial id="350532"/><TrialEndDateActual/><TrialEndDateCalc/><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="115970">live-attenuated viral vaccine (sc, measles/rubella virus infection), Indian Immunologicals</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>55</Patients><ProtocolTitle>A clinical trial to evaluate the safety and immunogenicity of HBI Measles and Rubella vaccine (Live) in two age groups of healthy male subjects</ProtocolTitle><Trial id="377732"/><TrialEndDateActual/><TrialEndDateCalc>2020-10-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-04-17 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>822</Patients><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Trial id="60653"/><TrialEndDateActual>2001-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2001-12-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2001-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2000-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Trial id="94105"/><TrialEndDateActual>2015-04-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-05-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-04-16 00:00:00</TrialEndDateGiven><TrialStartDate>2012-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>5803</Patients><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Trial id="11418"/><TrialEndDateActual>2006-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-03-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1128</Patients><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Trial id="9949"/><TrialEndDateActual>2009-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-04-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>458</Patients><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Trial id="102759"/><TrialEndDateActual>2006-11-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-11-01 00:00:00</TrialEndDateGiven><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>970</Patients><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Trial id="11388"/><TrialEndDateActual>2005-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-11-14 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>74</Patients><ProtocolTitle>Measles, Mumps, and Rubella (MMR) Immunity in College Students</ProtocolTitle><Trial id="59758"/><TrialEndDateActual>2012-12-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2012-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2012-12-01 00:00:00</TrialEndDateGiven><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>970</Patients><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Trial id="11388"/><TrialEndDateActual>2005-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-11-14 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56585">Vaxelis</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Trial id="124248"/><TrialEndDateActual>2015-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>240</Patients><ProtocolTitle>Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single- Dose and Multidose Presentations</ProtocolTitle><Trial id="106360"/><TrialEndDateActual>2013-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4011</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Trial id="88475"/><TrialEndDateActual>2015-11-09 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-19 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-11-09 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>21</Patients><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><Trial id="15250"/><TrialEndDateActual>2001-10-10 00:00:00</TrialEndDateActual><TrialEndDateCalc>2000-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2001-10-10 00:00:00</TrialEndDateGiven><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="30177">Menactra</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1378</Patients><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Trial id="9965"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-12-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="30177">Menactra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1664</Patients><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Trial id="9967"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="6621">Havrix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Trial id="94105"/><TrialEndDateActual>2015-04-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-05-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-04-16 00:00:00</TrialEndDateGiven><TrialStartDate>2012-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Trial id="187831"/><TrialEndDateActual>2006-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="60890">SA-14-14-2</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>628</Patients><ProtocolTitle>Evaluation of the immunogenicity and safety of Japanese encephalitis vaccine when given with measles-mumps-rubella vaccine</ProtocolTitle><Trial id="268796"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2016-10-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="39031">Menveo</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Trial id="10223"/><TrialEndDateActual>2009-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-12-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="89684">M-M-RvaxPRO</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Trial id="85664"/><TrialEndDateActual>2013-09-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-27 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55366">Nimenrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Trial id="124248"/><TrialEndDateActual>2015-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Trial id="91153"/><TrialEndDateActual>2015-08-18 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-08-18 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1620</Patients><ProtocolTitle>Comparative Study of Immunogenicity and Safety of a two-dose Regimen of ProQuad Manufactured With rHA</ProtocolTitle><Trial id="11632"/><TrialEndDateActual>2008-12-29 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-05-14 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-12-29 00:00:00</TrialEndDateGiven><TrialStartDate>2007-11-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4011</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Trial id="88475"/><TrialEndDateActual>2015-11-09 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-19 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-11-09 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1220</Patients><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Trial id="79465"/><TrialEndDateActual>2012-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2012-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>799</Patients><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><Trial id="15301"/><TrialEndDateActual/><TrialEndDateCalc>2005-10-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-05-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Trial id="94105"/><TrialEndDateActual>2015-04-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-05-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-04-16 00:00:00</TrialEndDateGiven><TrialStartDate>2012-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Trial id="11515"/><TrialEndDateActual>2007-07-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-04-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2007-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2007-07-01 00:00:00</TrialEndDateGiven><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Trial id="60050"/><TrialEndDateActual>2011-02-21 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-02-21 00:00:00</TrialEndDateGiven><TrialStartDate>2009-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1783</Patients><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Trial id="11526"/><TrialEndDateActual>2009-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-05-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>799</Patients><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><Trial id="15301"/><TrialEndDateActual/><TrialEndDateCalc>2005-10-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-05-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Trial id="187831"/><TrialEndDateActual>2006-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>467</Patients><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><Trial id="17279"/><TrialEndDateActual/><TrialEndDateCalc>2007-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="97346">measles vaccine, Cadila Healthcare</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>327</Patients><ProtocolTitle>Clinical Study To Compare The Immune Response And Safety Of Measles Vaccine Manufactured By Cadila Healthcare Ltd, With Measles Vaccine Manufactured By Serum Institute Of India Ltd, In Children 9 to 12 Months Of Age</ProtocolTitle><Trial id="229988"/><TrialEndDateActual/><TrialEndDateCalc>2016-12-11 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2015-05-12 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore</ProtocolTitle><Trial id="11425"/><TrialEndDateActual>2001-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2002-05-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2001-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2000-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1960</Patients><ProtocolTitle>Long-term Follow-up of Measles Antibodies</ProtocolTitle><Trial id="14946"/><TrialEndDateActual>2007-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2003-10-31 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2002-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47199">Adacel</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><Trial id="265194"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="89684">M-M-RvaxPRO</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>6500</Patients><ProtocolTitle>MMR at 6 Months Trial</ProtocolTitle><Trial id="364134"/><TrialEndDateActual/><TrialEndDateCalc>2020-10-12 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2023-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2023-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2019-04-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="95202">MRBEV</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>600</Patients><ProtocolTitle>A clinical trial to assess the safety and protective efficacy of Biological Es Measles-Rubella Vaccine in 9 to 12 months old Infants in India</ProtocolTitle><Trial id="266205"/><TrialEndDateActual/><TrialEndDateCalc>2018-01-27 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2016-07-29 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="14289">malaria vaccine, GlaxoSmithKline/Malaria Vaccine Initiative</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>700</Patients><ProtocolTitle>Immunogenicity and safety of GSK Biologicals malaria vaccine given at 6,7.5 and 9 months of age coadministered with measles,rubella and yellow fever vaccines</ProtocolTitle><Trial id="261663"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-17 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2016-09-14 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54328">MVA-mBN85B</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A Phase I Study of MVA-BN Vector Vaccine to Evaluate Safety and Immunogenicity in Healthy Volunteers</ProtocolTitle><Trial id="9026"/><TrialEndDateActual/><TrialEndDateCalc>2009-06-08 07:30:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2007-11-06 19:30:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="17821">Infanrix HeXa</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>955</Patients><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><Trial id="10599"/><TrialEndDateActual>2008-03-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-03-27 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>405</Patients><ProtocolTitle>ProQuad Intramuscular versus Subcutaneous</ProtocolTitle><Trial id="11634"/><TrialEndDateActual>2007-05-11 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-03-21 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2007-05-11 00:00:00</TrialEndDateGiven><TrialStartDate>2006-10-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1378</Patients><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Trial id="9965"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-12-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1412</Patients><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><Trial id="184151"/><TrialEndDateActual>2014-01-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-04 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-01-27 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3388</Patients><ProtocolTitle>Safety Study of ProQuad rHA in Infants</ProtocolTitle><Trial id="11426"/><TrialEndDateActual>2008-11-24 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-04-08 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-11-24 00:00:00</TrialEndDateGiven><TrialStartDate>2007-10-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>507</Patients><ProtocolTitle>Safety Study of a Refrigerator-Stable Formulation of Varivax</ProtocolTitle><Trial id="11524"/><TrialEndDateActual>2005-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-07-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2004-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4011</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Trial id="88475"/><TrialEndDateActual>2015-11-09 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-19 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-11-09 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10530">Comvax</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>822</Patients><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Trial id="60653"/><TrialEndDateActual>2001-12-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2001-12-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2001-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2000-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>799</Patients><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><Trial id="15301"/><TrialEndDateActual/><TrialEndDateCalc>2005-10-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2004-05-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>498</Patients><ProtocolTitle>Immunogenicity and Safety Study of GSK Biologicals 208136 Vaccine Formulated With New Measles and Rubella Working Seeds</ProtocolTitle><Trial id="54026"/><TrialEndDateActual>2010-12-13 00:00:00</TrialEndDateActual><TrialEndDateCalc>2010-12-02 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-12-13 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>149</Patients><ProtocolTitle>A Study To Determine If Upper Respiratory Tract Infection (URI) Affects The Seroconversion Rate Or Quantitative Response To Each Component Of ProQuad</ProtocolTitle><Trial id="15334"/><TrialEndDateActual/><TrialEndDateCalc>1996-06-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1994-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>5803</Patients><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Trial id="11418"/><TrialEndDateActual>2006-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-03-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Trial id="60050"/><TrialEndDateActual>2011-02-21 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-02-21 00:00:00</TrialEndDateGiven><TrialStartDate>2009-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1390</Patients><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><Trial id="15243"/><TrialEndDateActual/><TrialEndDateCalc>2001-03-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-09-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>21</Patients><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><Trial id="15250"/><TrialEndDateActual>2001-10-10 00:00:00</TrialEndDateActual><TrialEndDateCalc>2000-06-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2001-10-10 00:00:00</TrialEndDateGiven><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Trial id="124248"/><TrialEndDateActual>2015-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>458</Patients><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Trial id="102759"/><TrialEndDateActual>2006-11-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-11-01 00:00:00</TrialEndDateGiven><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>458</Patients><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Trial id="102759"/><TrialEndDateActual>2006-11-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-11-01 00:00:00</TrialEndDateGiven><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1412</Patients><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><Trial id="184151"/><TrialEndDateActual>2014-01-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-04 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-01-27 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6621">Havrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1783</Patients><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Trial id="11526"/><TrialEndDateActual>2009-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-05-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5</Patients><ProtocolTitle>Safety and Efficacy of ProQuad in Children 6 to 24 Months Being Evaluated for Solid Organ Transplant</ProtocolTitle><Trial id="254035"/><TrialEndDateActual>2016-11-03 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-06-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-11-03 00:00:00</TrialEndDateGiven><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>8309</Patients><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality</ProtocolTitle><Trial id="198691"/><TrialEndDateActual/><TrialEndDateCalc>2014-03-02 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="84867">Vaxem HIB</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Trial id="10223"/><TrialEndDateActual>2009-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-12-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Trial id="233238"/><TrialEndDateActual/><TrialEndDateCalc>2017-03-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14438">Avaxim</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>470</Patients><ProtocolTitle>Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine</ProtocolTitle><Trial id="11423"/><TrialEndDateActual>2010-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-05-23 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="101326">MV-NIS (lung cancer), Vyriad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>4</Patients><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Trial id="273428"/><TrialEndDateActual>2018-01-19 00:00:00</TrialEndDateActual><TrialEndDateCalc>2020-12-21 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-01-19 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-03 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72699">atezolizumab</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>4</Patients><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Trial id="273428"/><TrialEndDateActual>2018-01-19 00:00:00</TrialEndDateActual><TrialEndDateCalc>2020-12-21 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-01-19 00:00:00</TrialEndDateGiven><TrialStartDate>2017-08-03 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>432</Patients><ProtocolTitle>Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><Trial id="298150"/><TrialEndDateActual/><TrialEndDateCalc>2020-05-20 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2020-01-20 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2020-01-20 00:00:00</TrialEndDateGiven><TrialStartDate>2018-11-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><Trial id="265194"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="97994">MMRV vaccine, Zydus Cadila Healthcare</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>To Assess the Safety and Tolerability of Measles, Mumps, Rubella and Varicella Vaccine (Live-Attenuated, Freeze-Dried) in Healthy Adult Male Human Subjects</ProtocolTitle><Trial id="243853"/><TrialEndDateActual/><TrialEndDateCalc>2017-04-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2015-10-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="89684">M-M-RvaxPRO</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Trial id="124248"/><TrialEndDateActual>2015-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7080">Pneumovax 23</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><Trial id="10810"/><TrialEndDateActual>2004-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2003-05-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2004-11-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2004-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2001-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Trial id="11515"/><TrialEndDateActual>2007-07-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-04-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2007-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2007-07-01 00:00:00</TrialEndDateGiven><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Trial id="77052"/><TrialEndDateActual>2013-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-09-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>400</Patients><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Trial id="187831"/><TrialEndDateActual>2006-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1390</Patients><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><Trial id="15243"/><TrialEndDateActual/><TrialEndDateCalc>2001-03-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1999-09-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55366">Nimenrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1000</Patients><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Trial id="9859"/><TrialEndDateActual>2008-03-26 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-03-26 00:00:00</TrialEndDateGiven><TrialStartDate>2007-06-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1439</Patients><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Trial id="11389"/><TrialEndDateActual>2005-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-11-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Trial id="124248"/><TrialEndDateActual>2015-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>752</Patients><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><Trial id="11525"/><TrialEndDateActual>2006-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Trial id="91153"/><TrialEndDateActual>2015-08-18 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-08-18 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>5016</Patients><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Trial id="94105"/><TrialEndDateActual>2015-04-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-05-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-04-16 00:00:00</TrialEndDateGiven><TrialStartDate>2012-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="30177">Menactra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1128</Patients><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Trial id="9949"/><TrialEndDateActual>2009-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-04-19 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>970</Patients><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Trial id="11388"/><TrialEndDateActual>2005-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-11-14 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="30214">diphtheria/tetanus/pertussis vaccine, sanofi pasteur</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Trial id="77052"/><TrialEndDateActual>2013-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-09-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="39031">Menveo</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>2475</Patients><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Trial id="340960"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-24 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Trial id="44865"/><TrialEndDateActual>2008-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-08-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="99518">JVC-001</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>Non-blind, randomized trial to evaluate the safety and immunogenicity of JVC-001 intended for Japanese healthy children</ProtocolTitle><Trial id="244020"/><TrialEndDateActual/><TrialEndDateCalc>2017-04-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2015-10-05 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="89684">M-M-RvaxPRO</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>150</Patients><ProtocolTitle>Third MMR Vaccine Dose In Young Adults</ProtocolTitle><Trial id="270107"/><TrialEndDateActual/><TrialEndDateCalc>2018-03-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2018-05-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2018-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2016-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="102979">quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>2475</Patients><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Trial id="340960"/><TrialEndDateActual/><TrialEndDateCalc>2020-04-24 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2022-12-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2022-12-31 00:00:00</TrialEndDateGiven><TrialStartDate>2018-04-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>628</Patients><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><Trial id="269874"/><TrialEndDateActual/><TrialEndDateCalc>2018-04-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2017-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2017-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4144">Prevnar</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>300</Patients><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><Trial id="10810"/><TrialEndDateActual>2004-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2003-05-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2004-11-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2004-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2001-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3263">Vaqta</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1800</Patients><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><Trial id="11511"/><TrialEndDateActual>2008-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-10-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="49241">Quadracel</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Trial id="77052"/><TrialEndDateActual>2013-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-09-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54328">MVA-mBN85B</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>90</Patients><ProtocolTitle>Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years</ProtocolTitle><Trial id="59936"/><TrialEndDateActual>2010-08-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-01-30 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2010-08-31 00:00:00</TrialEndDateGiven><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1551</Patients><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><Trial id="60684"/><TrialEndDateActual>2000-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2000-10-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2000-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>1999-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>955</Patients><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><Trial id="10599"/><TrialEndDateActual>2008-03-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-11-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-03-27 00:00:00</TrialEndDateGiven><TrialStartDate>2007-01-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>752</Patients><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><Trial id="11525"/><TrialEndDateActual>2006-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2006-07-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1783</Patients><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Trial id="11526"/><TrialEndDateActual>2009-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-05-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Trial id="91153"/><TrialEndDateActual>2015-08-18 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-08-18 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Trial id="85664"/><TrialEndDateActual>2013-09-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-27 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>218</Patients><ProtocolTitle>A Phase III Study Of Prophylactic Antibiotics in Measles</ProtocolTitle><Trial id="11380"/><TrialEndDateActual>2001-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>1999-09-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2005-06-30 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2001-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>1998-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><Trial id="15317"/><TrialEndDateActual/><TrialEndDateCalc>1999-06-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><Trial id="15335"/><TrialEndDateActual/><TrialEndDateCalc>1988-06-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1986-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Trial id="85664"/><TrialEndDateActual>2013-09-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-27 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="9474">Varilrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>5803</Patients><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Trial id="11418"/><TrialEndDateActual>2006-10-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-03-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2006-10-31 00:00:00</TrialEndDateGiven><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><Trial id="17509"/><TrialEndDateActual/><TrialEndDateCalc>1999-07-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="22877">RotaTeq</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>312</Patients><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Trial id="124248"/><TrialEndDateActual>2015-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2015-01-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Trial id="132011"/><TrialEndDateActual>2013-08-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-08-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-08-01 00:00:00</TrialEndDateGiven><TrialStartDate>2013-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Trial id="203343"/><TrialEndDateActual>2015-12-22 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-02-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-12-22 00:00:00</TrialEndDateGiven><TrialStartDate>2014-08-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Trial id="132011"/><TrialEndDateActual>2013-08-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-08-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-08-01 00:00:00</TrialEndDateGiven><TrialStartDate>2013-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><Trial id="17509"/><TrialEndDateActual/><TrialEndDateCalc>1999-07-01 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4050</Patients><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso</ProtocolTitle><Trial id="200688"/><TrialEndDateActual/><TrialEndDateCalc>2014-12-31 12:00:00</TrialEndDateCalc><TrialEndDateEstimate>2016-03-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2016-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2013-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>30</Patients><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Trial id="44865"/><TrialEndDateActual>2008-05-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2009-08-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-05-31 00:00:00</TrialEndDateGiven><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="42065">Bexsero</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Trial id="233238"/><TrialEndDateActual/><TrialEndDateCalc>2017-03-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="95202">MRBEV</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1000</Patients><ProtocolTitle>A Post Licensure Clinical Trial to Assess the Safety and Tolerability of BEs Measles-rubella Vaccine in 9 to 12 Months Old Healthy Infants in a Single-Dose</ProtocolTitle><Trial id="378426"/><TrialEndDateActual/><TrialEndDateCalc>2020-10-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2019-04-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>263</Patients><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><Trial id="268409"/><TrialEndDateActual>2018-04-16 00:00:00</TrialEndDateActual><TrialEndDateCalc>2018-04-03 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2018-04-16 00:00:00</TrialEndDateGiven><TrialStartDate>2016-08-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="113162">MRVAC</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>756</Patients><ProtocolTitle>Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (phase III)</ProtocolTitle><Trial id="357452"/><TrialEndDateActual>2016-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-10-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>450</Patients><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Trial id="60050"/><TrialEndDateActual>2011-02-21 00:00:00</TrialEndDateActual><TrialEndDateCalc>2011-05-10 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2011-02-21 00:00:00</TrialEndDateGiven><TrialStartDate>2009-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1378</Patients><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Trial id="9965"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-12-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Trial id="11515"/><TrialEndDateActual>2007-07-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2007-04-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2007-07-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2007-07-01 00:00:00</TrialEndDateGiven><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1800</Patients><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><Trial id="11511"/><TrialEndDateActual>2008-01-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-10-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2008-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>3340</Patients><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Trial id="77052"/><TrialEndDateActual>2013-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2012-09-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>4000</Patients><ProtocolTitle>A Comparative Study To Evaluate The Efficacy Of Priorix With ROR Vax</ProtocolTitle><Trial id="15245"/><TrialEndDateActual/><TrialEndDateCalc>2000-06-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1200</Patients><ProtocolTitle>Study to evaluate frozen versus refrigerated MMRV (combined Measles, Mumps, Rubella, and Varicella) investigational vaccine</ProtocolTitle><Trial id="12456"/><TrialEndDateActual>2003-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2004-03-30 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2003-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10593">Meningitec</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>716</Patients><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><Trial id="83852"/><TrialEndDateActual>2014-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-08-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1664</Patients><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Trial id="9967"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1736</Patients><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Trial id="203343"/><TrialEndDateActual>2015-12-22 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-02-22 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-12-22 00:00:00</TrialEndDateGiven><TrialStartDate>2014-08-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="57017">Kinrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4011</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Trial id="88475"/><TrialEndDateActual>2015-11-09 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-19 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-11-09 00:00:00</TrialEndDateGiven><TrialStartDate>2012-06-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>1664</Patients><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Trial id="9967"/><TrialEndDateActual>2009-04-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-07-20 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-04-30 00:00:00</TrialEndDateGiven><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>284</Patients><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Trial id="85664"/><TrialEndDateActual>2013-09-27 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-12-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-27 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients/><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><Trial id="15317"/><TrialEndDateActual/><TrialEndDateCalc>1999-06-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47279">ProQuad</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>165</Patients><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><Trial id="15333"/><TrialEndDateActual/><TrialEndDateCalc>1998-06-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>25</Patients><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><Trial id="15335"/><TrialEndDateActual/><TrialEndDateCalc>1988-06-15 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1986-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients><ProtocolTitle>A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices</ProtocolTitle><Trial id="85837"/><TrialEndDateActual>2013-09-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-10-31 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-09-30 00:00:00</TrialEndDateGiven><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>110</Patients><ProtocolTitle>A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group</ProtocolTitle><Trial id="11384"/><TrialEndDateActual>2000-11-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2002-01-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2001-08-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2000-11-30 00:00:00</TrialEndDateGiven><TrialStartDate>1999-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>200</Patients><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Trial id="132011"/><TrialEndDateActual>2013-08-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-08-11 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2013-08-01 00:00:00</TrialEndDateGiven><TrialStartDate>2013-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>732</Patients><ProtocolTitle>A Phase IV, Open, Multicentric, Post-marketing Surveillance Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals Live Attenuated Measles-Mumps-Rubella vaccine (Priorix) in Korean Subjects Administered According to the Prescribing Information</ProtocolTitle><Trial id="172850"/><TrialEndDateActual>2005-08-19 00:00:00</TrialEndDateActual><TrialEndDateCalc>2001-02-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2005-08-19 00:00:00</TrialEndDateGiven><TrialStartDate>1999-08-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><Endpoint>Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>100</Patients><ProtocolTitle>Immunological Effect of Early Extra MMR Immunization in Infants Between 6 and 12 Months of Age in an Outbreak Setting</ProtocolTitle><Trial id="156178"/><TrialEndDateActual/><TrialEndDateCalc>2015-03-24 12:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2013-08-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>4000</Patients><ProtocolTitle>A Comparative Study To Evaluate The Efficacy Of Priorix With ROR Vax</ProtocolTitle><Trial id="15245"/><TrialEndDateActual/><TrialEndDateCalc>2000-06-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>716</Patients><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><Trial id="83852"/><TrialEndDateActual>2014-03-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2013-08-29 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2014-03-31 00:00:00</TrialEndDateGiven><TrialStartDate>2012-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3643">M-M-R II</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>165</Patients><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><Trial id="15333"/><TrialEndDateActual/><TrialEndDateCalc>1998-06-16 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>14</Patients><ProtocolTitle>Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR</ProtocolTitle><Trial id="218981"/><TrialEndDateActual>2017-11-01 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-03 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-11-01 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15298">Pentacel</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>216</Patients><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Trial id="10223"/><TrialEndDateActual>2009-06-30 00:00:00</TrialEndDateActual><TrialEndDateCalc>2008-12-31 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2009-06-30 00:00:00</TrialEndDateGiven><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>1560</Patients><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><Trial id="161697"/><TrialEndDateActual>2016-07-31 00:00:00</TrialEndDateActual><TrialEndDateCalc>2016-08-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2016-07-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="6621">Havrix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>4538</Patients><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Trial id="91153"/><TrialEndDateActual>2015-08-18 00:00:00</TrialEndDateActual><TrialEndDateCalc>2014-04-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2015-08-18 00:00:00</TrialEndDateGiven><TrialStartDate>2012-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="95202">MRBEV</Drug><Endpoint>Safety</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>Y</OriginatorSponsored><Patients>24</Patients><ProtocolTitle>A phase-I study to evaluate the safety and tolerability of Measles Rubella(MR) vaccine in 4 to 5 years old healthy children in a single-dose schedule</ProtocolTitle><Trial id="246741"/><TrialEndDateActual/><TrialEndDateCalc>2017-05-25 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven/><TrialStartDate>2015-11-25 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>873</Patients><ProtocolTitle>Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine</ProtocolTitle><Trial id="298801"/><TrialEndDateActual>2017-02-28 00:00:00</TrialEndDateActual><TrialEndDateCalc>2017-09-28 00:00:00</TrialEndDateCalc><TrialEndDateEstimate/><TrialEndDateGiven>2017-02-28 00:00:00</TrialEndDateGiven><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><Endpoint>Safety,Efficacy</Endpoint><Indication id="1">Measles virus infection</Indication><OriginatorSponsored>N</OriginatorSponsored><Patients>213</Patients><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Trial id="233238"/><TrialEndDateActual/><TrialEndDateCalc>2017-03-09 00:00:00</TrialEndDateCalc><TrialEndDateEstimate>2019-01-31 00:00:00</TrialEndDateEstimate><TrialEndDateGiven>2019-01-31 00:00:00</TrialEndDateGiven><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row></Rowset>